Onvara 0,5 ml Powder
PDF Leaflet Revision Date: 06 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Vaccination against varicella in individuals from 12 months of age.
Dosage (summary)
0.5 ml subcutaneously for all ages; second dose at least 3 months later for children, 4-8 weeks later for adolescents/adults.
Special Populations
- Immunocompromised
- Pregnant women
- Children with HIV
Pregnancy & Breastfeeding
Not recommended during pregnancy; caution advised during breastfeeding.
Key Drug Interactions
- Avoid salicylates for 6 weeks post-vaccination
- Defer vaccination for 5 months after blood/plasma transfusions
Contraindications
- Hypersensitivity to vaccine components
- Immunosuppressive therapy
- Active untreated tuberculosis
- Febrile illness >38.5u00b0C
Common side effects
- Injection site pain
- Fever
- Varicella-like rash
Counselling Points
- Administer immediately after reconstitution
- Avoid close contact with high-risk individuals for 6 weeks post-vaccination
- Discard if not used within 30 minutes after reconstitution
Serious warnings
- Risk of anaphylactoid reactions
- Transmission of vaccine virus possible
Important Disclaimer
The Onvara 0,5 ml Powder professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
